Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase.
Qingxia ZhangQian DingSuying YanQun-Ying YuePublished in: European journal of clinical pharmacology (2022)
Fatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors. The fatal AEs mainly manifested as serious bleeding, and most of them occurred in patients with concurrent multiple risk factors. Monitoring coagulation during rivaroxaban treatment is recommended in very high-risk ASCVD populations, and attention should be paid to prevention of medication errors.
Keyphrases
- atrial fibrillation
- adverse drug
- venous thromboembolism
- risk factors
- low dose
- pulmonary embolism
- electronic health record
- cardiovascular events
- antiplatelet therapy
- patient safety
- healthcare
- percutaneous coronary intervention
- working memory
- middle aged
- emergency department
- type diabetes
- squamous cell carcinoma
- locally advanced
- machine learning
- big data
- combination therapy
- oxidative stress
- data analysis
- community dwelling
- smoking cessation
- brain injury